title: Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
authors.forename: N
authors.initials: N
authors.lastname: Abramson
authors.forename: P K
authors.initials: PK
authors.lastname: Stokes
authors.forename: Mathew
authors.initials: M
authors.lastname: Luke
authors.forename: Alan R
authors.initials: AR
authors.lastname: Marks
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Harris
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D018394:CA-125 Antigen / Q000032:analysis; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D013792:Thalidomide / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D018394:CA-125 Antigen; D013792:Thalidomide